LAUSR

ciation of ofatumumab, a human monoclonal CD20 antibody in patients with relapsed or refractory chronic lymphocytic leukemia: a phase 1-2 study. British Journal of Haematology, 150, 58–71. Korycka-Wołowiec, A., Wołowiec, D. & Robak, T. (2015) Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. Expert Opinion on Drug Safety, 14, 1945–1959. Levin, A.S., Otani, I.M., Lax, T., Hochberg, E. & Banerji, A. (2017) Reactions to rituximab in an outpatient infusion center: a 5-year review. The Journal of Allergy and Clinical Immunology: In Practice, 5, 107–113. Oldham, R.K. & Dillman, R.O. (2008) Monoclonal antibodies in cancer therapy: 25 years of progress. Journal of Clinical Oncology, 26, 1774– 1777. Schwartzberg, L.S., Stepanski, E.J., Fortner, B.V. & Houts, A.C. (2008) Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Supportive Care in Cancer, 16, 393–398. Wierda, W.G., Padmanabhan, S., Chan, G.W., Gupta, I.V., Lisby, S. & Osterborg, A; Hx-CD20406 Study Investigators. (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood, 118, 5126–5129.